Evidence map›Paper›PMID 37545849›Full record

ArticleEuropean urology open science2023

Selective Use of Neoadjuvant Targeted Therapy Is Associated with Greater Achievement of Partial Nephrectomy for High-complexity Renal Masses in a Solitary Kidney.

Worapat Attawettayanon, Yosuke Yasuda, Jj H Zhang, Akira Kazama, Nityam Rathi, Carlos Munoz-Lopez, Kieran Lewis, Snehi Shah, Jianbo Li, João Pedro Emrich Accioly and 11 more

Abstract read
In one paragraph

Article in European urology open science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Worapat AttawettayanonGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Yosuke YasudaGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Jj H ZhangGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Akira KazamaGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Nityam RathiGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Carlos Munoz-LopezGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Kieran LewisGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Snehi ShahGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Jianbo LiDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland, OH, USA.
João Pedro Emrich AcciolyGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Rebecca A CampbellGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Shetal ShahImaging Institute, Cleveland Clinic, Cleveland, OH, USA.
Andrew WoodGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Jihad KaoukGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Georges-Pascal HaberGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Mohamad EltemamyGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Venkatesh KrishnamurthiGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Robert AbouassalyGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Christopher WeightGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Ithaar DerweeshDepartment of Urology, School of Medicine, University of California-San Diego, La Jolla, CA, USA.
Steven C CampbellGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Partial nephrectomy (PN) is preferred for a renal mass in a solitary kidney (RMSK), although tumors with high complexity can be challenging. Objective: To evaluate the evolution of RMSK management with a focus on achievement of PN. Design setting and participants: Patients with nonmetastatic RMSK ( Outcome measurements and statistical analysis: Functional outcomes, adverse events and complications, dialysis-free survival, and recurrence-free survival (RFS) were the measures evaluated. Mann-Whitney and χ Results and limitations: Overall, the median RENAL score was 10 and the median tumor diameter was 5.2 cm. Demographic characteristics, tumor diameter, and RENAL scores were similar between the pre-TKI-era and TKI-era groups. In the TKI era, 23/53 patients (43%) with clear-cell histology were selected for neoadjuvant TKI. These 23 patients had a greater median tumor diameter (7.1 vs 4.4 cm; Conclusions: Management of RMSK with high tumor complexity is challenging. Selective use of TKI therapy was associated with greater use of PN, although a randomized study is needed. RFS mostly reflected aggressive tumor biology rather than failure of local management. Patient summary: For complex kidney tumors in patients with a single kidney, management is challenging. Use of drugs called tyrosine kinase inhibitors before surgery was associated with reductions in tumor size and greater ability to achieve partial kidney removal for cancer control. Most recurrences were metastatic, which reflects aggressive tumor biology rather than failure of surgery.

Indexed as

High tumor complexityNeoadjuvant therapyPartial nephrectomyRenal cell carcinomaSolitary kidneyTyrosine kinase inhibitors

Identifiers

PMID37545849
PMCPMC10403684

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.